DK2718312T3 - Behandling af tilstande forbundet med sepsis - Google Patents
Behandling af tilstande forbundet med sepsis Download PDFInfo
- Publication number
- DK2718312T3 DK2718312T3 DK12727919.8T DK12727919T DK2718312T3 DK 2718312 T3 DK2718312 T3 DK 2718312T3 DK 12727919 T DK12727919 T DK 12727919T DK 2718312 T3 DK2718312 T3 DK 2718312T3
- Authority
- DK
- Denmark
- Prior art keywords
- cxcr1
- levels
- cells
- chemokine
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/125—Adult respiratory distress syndrome
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Anesthesiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- External Artificial Organs (AREA)
Claims (4)
1. Bindingsreagens, der kan binde specifikt til kemokin-receptoren CXCR1 til anvendelse ved behandling af sepsis og/eller respiratorisk distress syndrom (RDS), hvor bindingsreagensen er immobiliseret på en fast bærer, der er indeholdt i en aferese-søjle, hvortil der påføres perifert blod fra en patient, således at CXCR1-eksprimerende celler fjernes fra patientens perifere blod.
2. Bindingsreagens til anvendelse ifølge krav 1, hvor: (i) sepsis er et systemisk inflammationssyndrom, eller formålet med behandlingen er at behandle eller forebygge multipelt organdysfunktionssyndrom, eller hvor RDS'et er akut RDS eller sepsis-associeret RDS; og/eller (ii) bindingsreagensen, der kan binde specifikt til CXCR1, er en agonist eller en antagonist af CXCR1; og/eller (iii) bindingsreagensen, der kan binde specifikt til CXCR1, er udvalgt blandt et antistof og et kemokin; og/eller (iv) CXCR1-eksprimerende celler er monocytter, makrofager eller neutrofiler; og/eller (v) patienten er blevet udvalgt til behandling på basis af detektering af en stigning i niveauet af CXCR1-eksprimerende celler, niveauer af ekspression af CXCR1 og/eller niveauer af celler med høj ekspression af CXCR1 i en prøve opnået fra patienten; og/eller (vi) 20-50 % af patientens blod påføres til søjlen i en enkelt behandling.
3. Fremgangsmåde til overvågning af progression af behandlingen ifølge et hvilket som helst af kravene 1 eller 2 omfattende at bestemme a) niveauerne af kemokin-receptor CXCR1-eksprimerende celler b) niveauer af ekspression af CXCR1; og/eller c) niveauer af celler med høj ekspression af CXCR1 i en prøve opnået fra et individ, hvor: (i) høje niveauer af CXCR1-eksprimerende celler, høje niveauer af ekspression af CXCR1 eller høje niveauer af celler med høj ekspression af CXCR1 eller øgede niveauer af CXCR1-eksprimerende celler sammenlignet med en kontrol, øgede niveauer af ekspression af CXCR1 sammenlignet med en kontrol eller øgede niveauer af celler med høj ekspression af CXCR1 sammenlignet med en kontrol indikerer tilstedeværelse eller progression af sepsis; (ii) reducerede niveauer af CXCR1 -eksprimerende celler, niveauer af ekspression af CXCR1 og/eller niveauer af celler med høj ekspression af CXCR1 kor-relerer med vellykket behandling.
4. Fremgangsmåde ifølge krav 3, hvor: (i) sepsis er et systemisk inflammationssyndrom, eller behandlingen forebygger multipelt organdysfunktionssyndrom, eller hvor RDS'et er akut RDS eller sepsis-associeret RDS; og/eller (ii) prøven er en prøve af perifert blod, eventuelt hvor de CXCR1-eksprimerende celler er neutrofiler; og/eller (iii) højere niveauer af CXCR1-eksprimerende celler, niveauer af ekspression af CXCR1 og/eller niveauer af celler med høj ekspression af CXCR1 korrelerer med mere aktiv sygdom; og/eller (iv) lave niveauer af CXCR1-eksprimerende celler, niveauer af ekspression af CXCR1 og/eller niveauer af celler med høj ekspression af CXCR1 korrelerer med en mangel på aktiv sygdom eller mindre aktiv sygdom; og/eller (v) øgede niveauer af CXCR1-eksprimerende celler, niveauer af ekspression af CXCR1 og/eller niveauer af celler med høj ekspression af CXCR1 indikerer progression af sygdom.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161496352P | 2011-06-13 | 2011-06-13 | |
PCT/GB2012/051354 WO2012172344A2 (en) | 2011-06-13 | 2012-06-13 | Treating conditions associated with sepsis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2718312T3 true DK2718312T3 (da) | 2018-10-15 |
Family
ID=46317440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12727919.8T DK2718312T3 (da) | 2011-06-13 | 2012-06-13 | Behandling af tilstande forbundet med sepsis |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2718312B1 (da) |
DK (1) | DK2718312T3 (da) |
ES (1) | ES2688081T3 (da) |
WO (1) | WO2012172344A2 (da) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014193597A1 (en) * | 2013-05-02 | 2014-12-04 | University Of Vermont And State Agricultural College | Leptin for treating systemic inflammatory response syndrome |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002537362A (ja) | 1999-02-22 | 2002-11-05 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | ビオチン化ケモカイン抗体複合体 |
US6723538B2 (en) * | 1999-03-11 | 2004-04-20 | Micromet Ag | Bispecific antibody and chemokine receptor constructs |
US7601692B2 (en) * | 2000-11-28 | 2009-10-13 | Compugen Ltd. | MCP-1 splice variants and methods of using same |
EP1745032B1 (en) * | 2004-05-12 | 2013-07-31 | Merck Sharp & Dohme Corp. | CXCR1 and CXCR2 chemokine antagonists |
DE102005036505A1 (de) * | 2004-07-30 | 2006-06-01 | Adexter Gmbh | Vorrichtung und Verfahren zum Isolieren von Zellen, Biopartikeln und/oder Molekülen aus Flüssigkeiten mit dem Ziel einer Anwendung zur Behandlung von Krankheiten des Menschen |
JP2008519039A (ja) * | 2004-11-04 | 2008-06-05 | ニュー イングランド メデカル センター ホスピタルズ インク | Gタンパク質共役型受容体アゴニストおよびアンタゴニストならびに使用方法 |
SI2021025T1 (sl) * | 2006-05-12 | 2017-02-28 | Ith Immune Therapy Holdings Ab | Postopek in sredstva za zdravljenje vnetne črevesne bolezni |
NO2321351T3 (da) | 2008-08-18 | 2018-03-31 | ||
KR101703785B1 (ko) * | 2008-09-10 | 2017-02-07 | 아이티에이치 임뮨 세라피 홀딩스 에이비 | 염증 증상의 치료 방법 |
-
2012
- 2012-06-13 ES ES12727919.8T patent/ES2688081T3/es active Active
- 2012-06-13 EP EP12727919.8A patent/EP2718312B1/en active Active
- 2012-06-13 WO PCT/GB2012/051354 patent/WO2012172344A2/en unknown
- 2012-06-13 DK DK12727919.8T patent/DK2718312T3/da active
Also Published As
Publication number | Publication date |
---|---|
WO2012172344A3 (en) | 2013-03-14 |
EP2718312A2 (en) | 2014-04-16 |
WO2012172344A2 (en) | 2012-12-20 |
ES2688081T3 (es) | 2018-10-30 |
EP2718312B1 (en) | 2018-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10429385B2 (en) | Treating conditions associated with sepsis | |
EP3693041A1 (en) | Treating cancer | |
EP2718723B1 (en) | Diagnosing and treating inflammatory bowel disease and irritable bowel syndrome | |
DK2718312T3 (da) | Behandling af tilstande forbundet med sepsis | |
WO2012172343A2 (en) | Treating primary sclerosing cholangitis | |
DK2718313T3 (da) | Behandling af respiratoriske tilstande | |
WO2012172336A2 (en) | Treating inflammatory skin diseases | |
WO2012172337A2 (en) | Treating cardiovascular disease | |
EP2718310B1 (en) | Treating mental disorders | |
DK2718311T3 (da) | Behandling af multipel sklerose | |
EP2717940B1 (en) | Treating conditions associated with metabolic syndrome | |
WO2012172345A2 (en) | Treating conditions associated with allergy | |
WO2012172339A2 (en) | Treating inflammatory arthritis |